Forced degradation studies of biopharmaceuticals

RSSL can assist in designing forced degradation studies using insightful feasibility analysis to identify CQAs or produce biosimilarity/comparability data.


To fully characterise biological products, it is necessary to define the degradation pathways by which they can be converted into other forms. However, if determined in real-time with stability studies, this process could take several years.  

BMA R2 5950 HR Istock 499694183 Shutterstock 1283997949 (1)


At RSSL, we apply forced degradation conditions - temperature, pH, redox, light, humidity and shear stress - to accelerate this process. This enables the production of enough drug degradation products (5-20%) to be useful in stability indicating method development and validation. 


In addition to conducting the studies, our technical experts can also build a robust regulatory compliant data package to support your regulatory submission.


Forced degradation studies are used to:


  • To identify natural degradation pathways and mechanisms (early phase work) 
  • To identify stability indicating characteristics 
  • To produce degraded material for impurity identification, assay testing and validation 
  • To gain additional information about the drug molecule 



To identify the optimal conditions, each drug will require a tailored forced degradation protocol. This optimisation is performed using a robust feasibility study resulting in the development of a bespoke method capable of achieving suitable drug degradation levels.

Contact us

Need to get in touch? Either complete the enquiry form or call us:

Switchboard: +44 (0)118 918 4000

Customer Services: +44 (0)118 918 4076

We value your trust when sharing your personal data with us. We always treat your data in a fair and respectful manner limited to the purpose above mentioned. If you would like to know more about how we handle your data, please read our privacy notice.